Research
Hormonal
Dual incretin agonists (GLP-1R/GIPR) such as tirzepatide offer superior weight loss and glycemic control compared to GLP-1 mono-agonists, with a safety profile comparable to mono-agonists.
Tirzepatide, a once-weekly injection targeting both GLP-1 and GIP receptors, has demonstrated significant weight loss (up to 22.5%) and improved blood sugar control in Phase 3 trials. Importantly, its side effect profile is similar to existing GLP-1 drugs, making it a highly effective option for managing obesity and type 2 diabetes.
StrongSupportsVERY_HIGH confidence
In its phase 3 trial in adults with obesity, the highest dose of 15 mg once weekly produced an average reduction in body weight of 22.5% after 72 weeks of treatment [91]... Critically, the most frequent adverse events with tirzepatide, mild to moderate gastrointestinal events... were not higher than semaglutide in SUPRASS-2 [97].
Why this rating
Based on Phase 3 trials, the gold standard for clinical efficacy.
Source
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01566-x
narrative_reviewCited 51×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Triple incretin agonists (GLP-1R/GIPR/GCGR) produce superior body weight reduction (up to 24.2%) compared to dual or mono-agonists, approaching the efficacy of bariatric surgery.Good
- GLP-1/Glucagon dual agonists (e.g., mazdutide, survodutide) produce greater weight loss and triglyceride reduction compared to GLP-1 mono-agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →